| Identification | Back Directory | [Name]
Etripamil | [CAS]
1593673-23-4 | [Synonyms]
MSP-2017
Etripamil
(-)-MSP-2017
(-)-MSP-2017
Ca2+ channels,Calcium Channel,MSP 2017,Etripamil,inhibit,Inhibitor,MSP2017,Ca channels
Benzoic acid, 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]methylamino]ethyl]-, methyl ester | [Molecular Formula]
C27H36N2O4 | [MOL File]
1593673-23-4.mol | [Molecular Weight]
452.59 |
| Chemical Properties | Back Directory | [Boiling point ]
593.8±50.0 °C(Predicted) | [density ]
1.079±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Ethanol : 120 mg/mL (265.14 mM; Need ultrasonic) | [form ]
Oil | [pka]
8.92±0.50(Predicted) | [color ]
Brown to wine red | [InChI]
InChI=1/C27H36N2O4/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t27-/s3 | [InChIKey]
VAZNEHLGJGSQEL-CPAURPOUNA-N | [SMILES]
C(OC)(=O)C1=CC=CC(CCN(CCC[C@@](C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C)=C1 |&1:15,r| |
| Hazard Information | Back Directory | [Uses]
Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells[1][2]. | [IC 50]
L-type calcium channel | [References]
[1] Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. DOI:10.1016/j.jacc.2018.04.082
[2] Milestone Pharmaceuticals Announces USAN Approval of Generic Name “Etripamil” for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia. |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|